HOXA9 and head and neck squamous cell carcinoma: In contrast to these observations, the HOXA9 promoter appears to be characterized by considerably higher methylation levels in pathological tissues, as compared to normal controls, and may therefore serve as an early diagnostic biomarker in patients with HNSCC [26].